Algorithmiq, a Helsinki-based quantum software company, has joined the QuEra Quantum Alliance to advance applications of neutral-atom quantum computers in healthcare and life sciences. This partnership focuses on accelerating drug discovery and treatment development by leveraging QuEra’s quantum computing technology alongside Algorithmiq’s algorithmic expertise.
QuEra, a Boston-based company specializing in neutral-atom quantum computing, provides scalable systems with advanced processing modes and coherence. These systems, available via public cloud platforms, enable dynamic qubit manipulation to address computational challenges. Algorithmiq develops quantum algorithms combining classical and quantum computing capabilities, particularly in drug design and development processes.
The collaboration seeks to solve complex problems that are computationally challenging for classical systems. By utilizing QuEra’s quantum hardware, Algorithmiq aims to achieve advancements in precision and efficiency for healthcare research. The partnership also reinforces the importance of neutral-atom quantum platforms in life sciences, a field requiring substantial computational resources for modeling and simulations.
This alliance highlights neutral-atom quantum computing’s potential for practical applications in industries requiring significant computational scalability and accuracy. Interested organizations can explore partnership opportunities through QuEra’s Partner Program to contribute to the development of quantum-enabled solutions.
For more details, visit QuEra’s press release here.
December 11, 2024
